312 related articles for article (PubMed ID: 34356864)
1.
Kayabolen A; Yilmaz E; Bagci-Onder T
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356864
[TBL] [Abstract][Full Text] [Related]
2. Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations.
Persico P; Lorenzi E; Losurdo A; Dipasquale A; Di Muzio A; Navarria P; Pessina F; Politi LS; Lombardi G; Santoro A; Simonelli M
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267433
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
4. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
5. Consequences of
Kaminska B; Czapski B; Guzik R; Król SK; Gielniewski B
Molecules; 2019 Mar; 24(5):. PubMed ID: 30857299
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
Guo C; Pirozzi CJ; Lopez GY; Yan H
Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
[TBL] [Abstract][Full Text] [Related]
7. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH in Gliomas: Role in Cancer and Treatment Options.
Solomou G; Finch A; Asghar A; Bardella C
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296846
[TBL] [Abstract][Full Text] [Related]
12. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.
Romanidou O; Kotoula V; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(5):421-436. PubMed ID: 30194083
[TBL] [Abstract][Full Text] [Related]
13. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.
Viswanath P; Chaumeil MM; Ronen SM
Front Oncol; 2016; 6():60. PubMed ID: 27014635
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
Gallus M; Kwok D; Lakshmanachetty S; Yamamichi A; Okada H
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509387
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
18. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
Wahl DR; Venneti S
Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
[TBL] [Abstract][Full Text] [Related]
19. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI.
de Godoy LL; Lim KC; Rajan A; Verma G; Hanaoka M; O'Rourke DM; Lee JYK; Desai A; Chawla S; Mohan S
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760422
[TBL] [Abstract][Full Text] [Related]
20. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
